93
Participants
Start Date
July 22, 2021
Primary Completion Date
April 16, 2024
Study Completion Date
April 16, 2024
Risperidone 3 mg
Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
Paliperidone Palmitate 50 mg eq.
Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
Paliperidone Palmitate 75 mg eq.
Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 100 mg eq.
Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 150 mg eq.
Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 175 mg eq.
Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 263 mg eq.
Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 350 mg eq.
Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 525 mg eq.
Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
CARAES Ndera Neuro-Psychiatric Hospital, Kigali
University Teaching Hospital of Butare(CHUB), Butare
Kibuye Referral Hospital, Kibuye
University Teaching Hospital of Kigali, Kigali
Rwamagana Provincial Hospital, Rwamagana
Lead Sponsor
Janssen-Cilag International NV
INDUSTRY